 5. In addition to the Key Exclusion Criteria above for all subjects, standard exclusion criteria for subjects with hepatic impairment in Phase 1 studies will be used. These include the presence of clinically significant illness requiring treatment where said illness is unrelated to their hepatitis, history of gastrointestinal surgery cholecystectomy and appendectomy are, however, permitted; history of significant drug, food, or seasonal allergies; weight change during the PreTreatment Phase; significant findings revealed by the history, physical, or clinical laboratory testing where said findings are unrelated to the subjects hepatitis, alcohol misuse, or caffeine intake within 72 hours of E7080 administration; participation in another clinical trial within 4 weeks of lenvatinib administration; receipt or donation of blood or blood products within 4 to 8 weeks of lenvatinib administration; engagement in strenuous exercise; unwillingness to abide by the study requirements; or, in the opinion of the investigator, unlikely to complete the study. 